Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04578600
Title CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Joseph Tuscano
Indications

MALT lymphoma

hairy cell leukemia

marginal zone B-cell lymphoma

lymphoplasmacytic lymphoma

mantle cell lymphoma

follicular lymphoma

chronic lymphocytic leukemia/small lymphocytic lymphoma

B-cell lymphoma

Therapies

Azacitidine + Lenalidomide + Obinutuzumab

Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
University of California Davis Comprehensive Cancer Center Recruiting Sacramento California 95817 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field